ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $5,899,000 | -14.7% | 241,871 | -9.8% | 0.00% | -20.0% |
| Q1 2021 | $6,919,000 | -48.8% | 268,183 | +6.2% | 0.01% | -50.0% |
| Q4 2020 | $13,502,000 | +30.0% | 252,571 | +0.3% | 0.01% | +11.1% |
| Q3 2020 | $10,389,000 | -12.2% | 251,844 | +3.2% | 0.01% | -25.0% |
| Q2 2020 | $11,826,000 | +11.5% | 243,994 | -2.8% | 0.01% | -7.7% |
| Q1 2020 | $10,608,000 | -11.4% | 251,085 | -10.2% | 0.01% | +18.2% |
| Q4 2019 | $11,967,000 | +49.5% | 279,727 | +25.8% | 0.01% | +37.5% |
| Q3 2019 | $8,004,000 | +139.2% | 222,403 | +77.7% | 0.01% | +100.0% |
| Q2 2019 | $3,346,000 | +19.1% | 125,171 | +19.7% | 0.00% | +33.3% |
| Q1 2019 | $2,809,000 | +63.7% | 104,600 | -1.4% | 0.00% | +50.0% |
| Q4 2018 | $1,716,000 | -29.1% | 106,100 | -9.0% | 0.00% | -33.3% |
| Q3 2018 | $2,421,000 | +25.6% | 116,600 | -7.6% | 0.00% | 0.0% |
| Q2 2018 | $1,927,000 | -43.4% | 126,200 | -16.7% | 0.00% | -40.0% |
| Q1 2018 | $3,404,000 | -28.8% | 151,500 | -4.6% | 0.01% | -16.7% |
| Q4 2017 | $4,781,000 | -17.2% | 158,800 | +3.7% | 0.01% | -33.3% |
| Q3 2017 | $5,771,000 | +37.6% | 153,200 | +1.9% | 0.01% | +28.6% |
| Q2 2017 | $4,195,000 | -17.0% | 150,400 | +2.2% | 0.01% | -12.5% |
| Q1 2017 | $5,057,000 | +14.2% | 147,100 | -4.2% | 0.01% | +14.3% |
| Q4 2016 | $4,427,000 | -9.3% | 153,500 | 0.0% | 0.01% | -12.5% |
| Q3 2016 | $4,883,000 | -8.3% | 153,500 | -6.5% | 0.01% | -11.1% |
| Q2 2016 | $5,327,000 | +12.6% | 164,100 | -3.0% | 0.01% | +12.5% |
| Q1 2016 | $4,731,000 | -31.6% | 169,200 | -12.8% | 0.01% | -27.3% |
| Q4 2015 | $6,916,000 | +8.3% | 194,000 | +0.5% | 0.01% | 0.0% |
| Q3 2015 | $6,386,000 | -21.0% | 193,100 | 0.0% | 0.01% | -8.3% |
| Q2 2015 | $8,087,000 | +28.9% | 193,100 | -2.4% | 0.01% | +33.3% |
| Q1 2015 | $6,274,000 | 0.0% | 197,923 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $6,274,000 | +44.7% | 197,923 | +13.0% | 0.01% | +50.0% |
| Q3 2014 | $4,337,000 | +5.9% | 175,148 | -3.4% | 0.01% | 0.0% |
| Q2 2014 | $4,097,000 | +9.9% | 181,365 | +2.1% | 0.01% | +20.0% |
| Q1 2014 | $3,728,000 | -25.7% | 177,655 | -9.9% | 0.01% | -28.6% |
| Q4 2013 | $5,018,000 | +15.9% | 197,250 | +25.2% | 0.01% | -12.5% |
| Q3 2013 | $4,329,000 | +88.8% | 157,600 | +24.7% | 0.01% | +60.0% |
| Q2 2013 | $2,293,000 | – | 126,350 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |